Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020 Kumar Jeetendra | June 23, 2020 Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical …
MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments Kumar Jeetendra | July 15, 2020 At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer. “Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via …
Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
FUJIFILM Irvine Scientific dispatches Sterile Express Media Service Kumar Jeetendra | December 4, 2020 FUJIFILM Irvine Scientific, Inc., today announced the launch of Sterile Express Media Service (SEMS), for small, rapid creation of non-GMP media tested for sterility. With SEMS, clients can request up to 100L of media, to be quickly manufactured in a Grade A/ISO 5 sterile environment, and have it shipped within 15 business days pending sterility …
